Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.


TSXV:RX - Post by User

Bullboard Posts
Comment by tkirk62on Mar 03, 2020 12:04pm
116 Views
Post# 30761213

RE:cheap, cheap, cheap!

RE:cheap, cheap, cheap!Care to share how you get your number? I get P/E ex-cash as something like 10.9x with a $5 share price.

Earnings through Q3 = $3.2 million. $3.2 million divided by 3 then times by 4 (to get a 2019 full year estimate) = $4.3 million. 

Cash on balance sheet at Q3 = $19.8 million. Minus $1.1 million spent on buybacks since Q3 plus $2 million estimated cash flow in Q4 = $20.7 million cash

Shares outstanding = 13.5 million. 13.5 million shares times $5 share price = $67.5 million market cap

$67.5 million market cap minus $20.7 million cash = $46.8 million

$46.8 million divided by $4.3 million = 10.9x P/E ex-cash. 

The onlything I can think of is my earnings number might be too low, so my P/E might be a bit high, but the ratio definitely isn't "well under 10x" unless I'm missing something major.
Bullboard Posts